Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. Oktober 2020 08:00 ET | Quelle: Janpix Inc.

Janpix Announces $10 Million Series B Financing to Advance STAT Protein Degrader Pipeline

CAMBRIDGE, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Janpix Inc., a biotechnology company developing monovalent small molecule protein degraders of STAT proteins as novel therapeutics, today...
15. Juni 2020 08:00 ET | Quelle: Janpix Inc.

Potent Preclinical Antitumor Activity Demonstrated by Janpix’s Selective STAT3 & STAT5 Monovalent Degraders to be presented at the Virtual Annual Meetings of the European Hematology Association and American Association for Cancer Research (Part II)

CAMBRIDGE, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Janpix Inc., a biotechnology company developing monovalent small molecule protein degraders as novel therapeutics, today announced the company...
12. Dezember 2019 11:34 ET | Quelle: Janpix Inc.

Janpix, Inc. Announces Appointment of Sanford (Sandy) Zweifach as Executive Chairman to its Board of Directors

–Addition of Experienced Executive to Leadership Team– CAMBRIDGE, Mass. and MISSISSAUGA, Ontario, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Janpix, Inc., a privately-held biopharmaceutical company...